Viral infections can affect the glycosylation pattern of glycoproteins involved in antiviral immunity. Given the importance of protein glycosylation for immune function, we investigated the effect that modulation of the highly conserved HLA class I N-glycan has on KIR: HLA interactions and NK cell function. We focused on HLA-B*57:01 and its interaction with KIR3DL1, which has been shown to play a critical role in determining the progression of a number of human diseases, including human immunodeficiency virus-1 infection. 721.221 cells stably expressing HLA-B*57:01 were treated with a panel of glycosylation enzyme inhibitors, and HLA class I expression and KIR3DL1 binding was quantified. In addition, the functional outcomes of HLA-B*57:01 N-glycan disruption/modulation on KIR3DL1ζ 
Introduction
Natural killer (NK) cells are part of the innate immune system, and serve as a first line of defense against intracellular pathogens and malignantly transformed cells. NK cells can lyse target cells via directed secretion of perforin and granzyme, antibody-dependent-cell-mediated-cytotoxicity and Fas/FasL-mediated cytotoxicity [1] , but can also activate and recruit other immune cells via secretion of pro-inflammatory cytokines and chemokines. The importance of NK cell function is highlighted in the setting of impaired NK cell function or NK cell deficiencies, which are associated with increased susceptibility to infections with viruses and intracellular bacteria [1] [2] [3] [4] . NK cell activity is regulated via a number of activating and inhibitory receptors, including killer cell immunoglobulin-like receptors (KIRs) [1, 5] , which recognize human leukocyte antigen (HLA) proteins. Binding of KIRs to HLA class I molecules is determined by the respective HLA class I and KIR allotypes, as well as the sequence of the HLA class I-presented peptides [6, 7] . While binding of inhibitory KIRs to HLA class I molecules results in NK cell inhibition, engagement of activating KIRs or loss of inhibitory KIR binding can lead to NK cell activation [8, 9] . The KIR-HLA interaction has been demonstrated to have an important impact on viral infections, including human immunodeficiency virus-1 (HIV-1). In HIV-1 positive individuals, KIR3DL1
+ NK cells expanded preferentially in the presence of HLA-Bw4-80I, the ligand class for KIR3DL1 [10, 11] . Protein glycosylation is a post-translational modification occurring in the endoplasmatic reticulum (ER) and Golgi apparatus. In multiple enzymatic steps, a complex oligosaccharide (i.e. glycan) is synthesized in the ER, transferred to a specific receptor sequence on its target protein, and subsequently cropped and remodeled in the ER and Golgi [12] . In the case of asparagine N-glycosylation, the target amino acid sequence on the respective proteins is N-X-S/T, where the glycan is bound to the asparagine. It is estimated that over 7,000 distinct glycan structures can be generated in mammals [13] , suggesting a wide range of functional properties, which can be modulated by differential glycosylation. On HLA-class I, the glycan at position N86, which is located close to the Bw4 motive critical for binding of KIR3DL1 to its ligands, is highly conserved and present on practically all HLA-class I allotypes [14, 15] . Here we use a panel of glycosylation inhibitors to examine the effects of glycosylation modifications on KIR3DL1:HLA-B Ã 57:01 interactions and their potential effect on NK cell function, with a more in-depth characterization of the effect tunicamycin (TUN)-an antibiotic that can completely block N-glycosylation in eukaryotic cells by preventing the linkage of the glycan to the asparagine [16, 17] -and castanospermine (CSP)-a α-glucosidase I and II inhibitor able to inhibit the glycan trimming in the ER necessary for the assembly of a fully functional glycan [17, 18] .
Materials and Methods

Target Cells
HLA class I-deficient 721.221 cells (referred to as '221 cells' or '221s' hereafter) stably expressing HLA-B Ã 08:01 or HLA-B Ã 57:01 were provided by Christian Brander (Ragon Institute of MGH, MIT and Harvard, Cambridge, MA) as previously described [19] . All cells were cultured at 37°C with 5% CO 2 in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Biochrom AG), 2500 U/mL penicillin and 2500 μg/mL streptomycin (Sigma-Aldrich) [20] unless stated otherwise. This media was referred to as 'R10'.
Glycosylation inhibition screening and titration
Glycosylation inhibition was performed by incubating target cells for 24 h at 37°C/5%CO 2 in R10 supplemented with different glycosylation inhibitors: 5 mM of 1-deoxynojirimycin (DNM) (Tocris Bioscience), 500 μM of australine (AUS) (Santa Cruz Biotechnology), 2 mM of castanospermine (CSP) (Tocris Bioscience), 100 μM of kifunensine (KIF) (Tocris Bioscience), 500 μM of 3F ax -peracetyl-Neu5Ac (STI) (Millipore), 100 μM of swainsonine (SWA) (Tocris Bioscience), 0.5μg/mL of tunicamycin (TUN) [21] (Sigma-Aldrich Chemie GmbH) or phosphate buffered saline (PBS) as a control. Optimal concentrations of glycosylation inhibitors were determined by using effective concentrations reported in the literature as well as lower and higher doses. Readouts measured were cell death of target cells and CD69 expression of KIR3DL1z-Jurkat cells after coincubating with glycosylation inhibitor treated HLA-B Ã 57:01-expressing target cells (see Jurkat reporter cell assay methods). 
Quantification of HLA class I expression and KIR3DL1 binding
NK cell cloning and degranulation assay
Primary human NK cells isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors were cloned by limiting dilution in the presence of feeders and maintained in NK cell cloning medium consisting of R10 supplemented with 5% human serum (Sigma-Aldrich), 1X MEM-NEAA (Gibco), 1X sodium pyruvate (Gibco), 100ug/mL Kanamycin, 200 U/mL IL-2 (AIDS Reagent Program, NIH) using a protocol adapted from a previously reported method [22] . Briefly, NK cells were isolated from peripheral blood mononuclear cells (PBMCs) from a KIR3DL1 + HLA-Bw4 + donor via magnetic negative selection (NK cell isolation kit from Miltenyi), added to a mix of irradiated feeders consisting of freshly isolated allogeneic (PBMCs) combined with log-phase-growth RPMI 8866 cells (Sigma-Aldrich) at a 10:1 ratio in cloning medium containing 1 μg/mL phytohaemagglutinin (PHA; Fisher) and mixed thoroughly before plating at 100 μL/well (0.5 NK cell/well) in 96-well plates and incubated for 14 days at 37°C/5% CO 2 . After 14 days, wells that had outgrowth of cells were transferred to 48-well plates and maintained in NK cell cloning medium with frequent media exchange (approximately every 3 days). Cells were phenotyped by flow cytometry to assess NK cell marker (e.g. CD56 and CD16) and KIR3DL1 expression. Degranulation assays were performed by co-incubating 5 × 10 4 NK cells with 2.5 × 10 5 target cells (effector-to-target cell ratio of 1:5) in 200 μL of R10 containing 3 μL of anti-CD107a-PE-Cy7 antibody (BioLegend) for 2 h at 37°C/5% CO 2 , and subsequently staining with anti-CD56-BV605 and anti-CD16-BV785 antibodies (both from BioLegend) for 30 min at 4°C, and then fixed with 4% paraformaldehyde/PBS. Flow cytometric analysis was performed on a BD LSRFortessa.
Ethics
PBMCs from healthy donors were obtained and frozen after obtaining written informed consent following procedures approved by the Partners Human Research Committee (ethics committee) and the Institutional Review Board of Massachusetts General Hospital. HLA-I types of selected human samples were determined prior to this study by high-resolution HLA-I typing performed at the HLA-typing laboratory of the National Cancer Institute, National Institutes of Health. KIR types were determined prior to this study by Sanger sequencing in the laboratory of Mary Carrington.
Statistics
Flow data was analyzed in FlowJo v10 (FlowJo LLC, Ashland, Oregon). Statistical analyses were performed using GraphPad Prism 6.0c (GraphPad Software Inc., La Jolla, California, USA Fig 1A and 1B) . The Golgi-resident sialyl transferase inhibitor (STI) tested, however, did not result in any significant change in HLA-B Ã 57:01 expression or KIR3DL1 binding. Inhibitors that targeted ER-resident α-glucosidase II (CSP, DNM), which is an enzyme necessary for the last removal of glucose from N-glycans to allow anterograde transport to the Golgi, dramatically reduced HLA-B Ã 57:01 expression and abrogated KIR3DL1 binding. The ER-resident α-glucosidase I-specific inhibitor (AUS) minimally increased HLA-B Ã 57:01 expression or KIR3DL1 binding (Fig 1A) . However, in the case of TUN, we observed a major decrease in KIR3DL1-Fc binding while HLA-B Ã 57:01 surface expression was increased slightly (Fig 1B) .
Thus, after preliminary testing of the effects that several different glycosylation inhibitors had on HLA class I expression and KIR binding, we decided to focus on TUN, the only inhibitor tested that did not decrease HLA class I surface expression but dramatically reduced KIR3DL1-Fc binding, and that had the unique function of completely inhibiting that addition of N-glycans. We subsequently performed a titration assay in order to identify the minimal amount of glycosylation inhibitors required to observe a strong functional effect on the binding of Higher doses of glycosylation inhibitors increased cell toxicity to a degree that interfered with our assay, as cell death of target cells rose dramatically if the concentrations of glycosylation inhibitors were increased over the recommended concentration. Lower doses of inhibitors increased signaling of KIR3DL1z Jurkat cells after coincubation, indicating a loss of inhibition of target cell glycosylation. Thus, we concentrated on the glycosylation inhibitor TUN at a concentration of 0.5 μg/mL, representing a similar concentration as used in previous studies on the effects of TUN on HLA class I glycosylation [23, 24] .
HLA class I N-glycan is necessary for KIR3DL1 binding to HLA-B*57:01
We next sought to quantitatively assess the effects of TUN on HLA-B MFI increase, p = 0.02; 2.0-fold W6/32 MFI increase, p < 0.0001) (Fig 2A, S1 Fig) Fig 3A) .
KIR3DL1z
-Jurkat cells were compared to untransduced Jurkat cells (data not shown) and no difference in activation after coincubation with HLA class I-expressing target cells was observed. Thus, KIR3DL1z -Jurkats were used as a negative control (Fig 3B and 3C ). and treatment with TUN had no effect (Fig 3C) . KIR3DL1z -(i.e. untransduced) Jurkat cells
were not activated after-co-incubation with any of the tested target cells regardless of TUN treatment (Fig 3B and 3C ). (Fig 4A) . KIR3DL1 + NK cells exposed to 221 cells degranulated extensively (74.47% ± 2.20% CD107a+), but were significantly suppressed when exposed to 221-HLA-B Ã 57:01 cells (27.20% ± 0.7% CD107a+, 2.7-fold decrease compared to the 221 samples, p < 0.0001), which was still significantly higher than unstimulated NK cells (0.46% ± 0.11% CD107a+) (Fig 4B) . However, TUN pre-treatment of 221-HLA-B Ã 57:01 cells resulted in a significant increase in degranulation (38.53% ± 1.37%
CD107a+, 1.4-fold increase compared to 221-B57, p < 0.0001) compared to untreated 221-HLA-B Ã 57:01 cells. KIR3DL1 -NK cells exposed to 221 cells (80.57% ± 1.87%) degranulated significantly more than when exposed to 221-B Ã 57 cells (66.7% ± 1.05%, 1. Discussion N-glycosylation is a critical step in post-translational protein modification with functional importance that is not yet fully understood. In the case of all HLA class I allotypes, a single, highly conserved N-glycosylation site is located at position N86 [14, 15] , in close proximity to the highly polymorphic motif spanning from amino acids 77 to 83, which constitutes the Bw4 motif in HLA-Bw4 alleles and is critical for KIR3DL1 binding to these [25] . We therefore hypothesized that HLA class I N-glycosylation can modulate binding between HLA-Bw4 proteins and KIR3DL1. To test this hypothesis, we employed a panel of glycosylation enzyme inhibitors to modify or eliminate N-glycan structures in HLA-B Ã 57:01-expressing cells and assessed HLA-B Ã 57:01 expression and binding to KIR3DL1. We demonstrate that presence of Reports of the importance of N-glycosylation for KIR:HLA binding are scarce, save for one study suggesting that the HLA class I N-glycan does not influence KIR binding [26] . In contrast, several studies reported the consequences of HLA class I N-glycosylation modifications on T-cell receptor (TCR) binding [23, [27] [28] [29] . Those reports all concluded that TCR binding to HLA class I (and MHC class I in mice) is independent of HLA class I glycosylation, given the relatively long distance between the TCR binding site and the HLA class I N86 glycan. KIR: HLA crystal structures, however, reveal a very close proximity between the KIR binding site on HLA class I and position N86, which in these structures is aglycosylated due to the production of these proteins in E. coli (Fig 5) . This suggests that the HLA class I N86 glycan may be contacting KIR and influencing binding avidity. Of note, the one study that concluded that HLA class I glycosylation was not necessary for KIR binding was based on a generally assumed interaction between HLA-B Ã 08:01 and an undiscovered inhibitory KIR, which later was found to not exist and only be the effects of the interaction between the inhibitory receptor NKG2A and HLA-E, which was not discovered at the time of the study [30] . Thus, to the best of our knowledge, our study is the first to implicate the HLA class I N-glycan as being critical for KIR: HLA binding, which may serve as another means of modulating the interaction between NK cell receptors and target cell ligands. It has been demonstrated that the glycosylation pattern of several immune receptor-ligand pairs can be influenced in the setting of infection. In HIV-1 infection, a global shift in the glycosylation pattern of IgG has been observed, with HIV-1-specific antibodies displaying the most distinct glycosylation patterns {Ackerman, 2013 #357} [31, 32] . This shift in IgG glycosylation patterns can alter Fc receptor binding and is associated with improved antiviral activity and control of HIV-1, but has also been described for other viral and bacterial infections [31, 33] . Indeed, the N-glycan structure found on IgG is very similar to the HLA class I N86 glycan, and can be modified similarly by the addition of fucose, bisecting N-acetyl glucosamine, galactose, or sialic acid [34] [35] [36] . Furthermore, HIV-1 infection has been shown to alter glycosylation in host cells, and it is conceivable that HIV-1 might affect HLA class I glycosylation, either as a host response mechanism or a direct immunevasive tactic depending on whether HLA class I binding to NK cell receptors is enhanced or diminished by the altered glycosylation pattern. It has been suggested that other viruses have taken advantage of this level of regulation, as in the case of hepatitis C virus, which downregulates HLA class I expression in order to escape immune pressure, a process that is hypothesized to be due to altered glycosylation [37] [38] [39] [40] .
While much about the role of modified glycosylation patterns remains to be elucidated, our data demonstrates the importance of glycosylation in KIR:HLA binding and that removal of the glycan has a functional effect on the activation of NK cells. The extent to which pathogens and the immune system can exploit this mechanism to their advantage or whether this mechanism can be harnessed for therapeutic purposes means remains to be determined. 
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